News

Mon, 03/06/2019
Publication: Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.
Muenster. For the first time scientists from the University of Münster could show that multiple sclerosis (MS) alters the energy metabolism of T cells during acute phases of disease exacerbation. Therapeutic interventions targeting the metabolism of activated T cells display new potential avenues for treatment of patients with MS affecting around 250,000 people in Germany. The […]...more
Mon, 29/04/2019
Publication: Calcium influx through plasma-membrane nanoruptures drives axon degeneration in a model of multiple sclerosis.
Munich.  Here SFB researchers from Munich use in vivo calcium imaging in a multiple sclerosis model to show that cytoplasmic calcium levels determine the choice between axon loss and survival. Calcium can enter the axon through nanoscale ruptures of the axonal plasma membrane that are induced in inflammatory lesions. Neuron doi: 10.1016/ j.neuron.2018.12.023...more
Tue, 04/12/2018
SFB 128 International Symposium
SFB 128. We are happy to announce the international Symposium of the Collaborative Research Centre 128 “Multiple Sclerosis” taking place from Sunday, September 15th, till Tuesday, September 17th, 2019 in the Rhine Main region. Full details of the event will follow....more


Thu, 09/11/2017 | Elisabeth Schuh received SEED funding

Munich. SFB 128 researcher Elisabeth Schuh, MD, has been honoured by a young scientist’s studentship within the KKNMS SEED program. In her project „The role of the NLRP3 inflammasome in multiple sclerosis and experimental autoimmune encephalomyelitis“, Dr. Schuh analyses the influence of the NLRP3in MS. NLRP is a cytosolic protein complex in monocytes, macrophages and neutrophil granolucytes that regulated the production of inflammatory cytokines of the interleukin-1 family. In her project, Dr. Schuh wants to identify the population of myeloid cells involved in MS pathogenesis, with the aim of finding new pathways for therapeutic intervention that prevent autoimmune tissue damage.
The SEED program addresses scientists younger than 32 years who have not yet completed their medical training. The maximum funding is 32.000 € or 75 percent of the project’s budget. The remaining 25% have to be paid by the stipend’s employee.